Back to search

Article

Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective Analysis

2025-12-22

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose</bold> Venetoclax, a selective BCL-2 inhibitor, demonstrates efficacy in acute leukemia (AL) but variable pharmacokinetics. Therapeutic drug monitoring (TDM) serves as a critical tool for evaluating the efficacy and safety of venetoclax therapy. This study explored the factors influencing plasma venetoclax concentrations and their correlation with febrile neutropenia (F...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f4ade9f9-bf29-5b02-b4a5-088348d2d3c6
DOI
10.21203/rs.3.rs-8247030/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisDOI 10.21203/rs.3.rs-8247030/v1
Association Between Venetoclax Concentration and Febrile Neutropenia in Acute Leukemia: A Retrospective AnalysisSemantic proximity
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective studySemantic proximity
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study.Semantic proximity
Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AMLSemantic proximity
Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaSemantic proximity
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity
Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity
Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemiaSemantic proximity
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSemantic proximity
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.